James Bridges
Concepts (332)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung | 27 | 2026 | 4109 | 1.790 |
Why?
| | Receptors, G-Protein-Coupled | 7 | 2026 | 233 | 1.410 |
Why?
| | Pulmonary Surfactants | 7 | 2025 | 102 | 1.310 |
Why?
| | Alveolar Epithelial Cells | 5 | 2021 | 120 | 1.120 |
Why?
| | Pulmonary Alveolar Proteinosis | 4 | 2024 | 16 | 1.010 |
Why?
| | Respiratory Mucosa | 5 | 2025 | 322 | 1.010 |
Why?
| | Glucocorticoids | 6 | 2023 | 535 | 0.890 |
Why?
| | Pulmonary Alveoli | 7 | 2025 | 383 | 0.850 |
Why?
| | Betamethasone | 5 | 2023 | 21 | 0.830 |
Why?
| | Idiopathic Pulmonary Fibrosis | 3 | 2026 | 691 | 0.770 |
Why?
| | Signal Transduction | 14 | 2026 | 5226 | 0.770 |
Why?
| | Gene Expression Regulation, Developmental | 5 | 2019 | 905 | 0.730 |
Why?
| | Epithelial Cells | 6 | 2023 | 1125 | 0.720 |
Why?
| | Transduction, Genetic | 2 | 2021 | 133 | 0.700 |
Why?
| | Dependovirus | 2 | 2021 | 79 | 0.690 |
Why?
| | Mice | 33 | 2026 | 18339 | 0.630 |
Why?
| | Regeneration | 2 | 2021 | 197 | 0.620 |
Why?
| | Animals | 50 | 2026 | 38058 | 0.620 |
Why?
| | Lipid Metabolism | 3 | 2024 | 527 | 0.610 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2017 | 161 | 0.610 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2018 | 297 | 0.530 |
Why?
| | Cell Adhesion | 2 | 2016 | 455 | 0.510 |
Why?
| | Lung Diseases | 4 | 2018 | 787 | 0.500 |
Why?
| | Cell Differentiation | 5 | 2023 | 2050 | 0.460 |
Why?
| | Fibroblasts | 4 | 2026 | 1034 | 0.440 |
Why?
| | Sterol Regulatory Element Binding Proteins | 1 | 2014 | 3 | 0.420 |
Why?
| | Pulmonary Surfactant-Associated Protein C | 5 | 2021 | 45 | 0.420 |
Why?
| | Fetal Organ Maturity | 4 | 2022 | 13 | 0.410 |
Why?
| | Peptides | 3 | 2022 | 995 | 0.410 |
Why?
| | Dermatitis, Allergic Contact | 2 | 2026 | 72 | 0.370 |
Why?
| | Adrenal Cortex Hormones | 3 | 2020 | 478 | 0.370 |
Why?
| | Allergens | 3 | 2026 | 384 | 0.360 |
Why?
| | Cell Membrane | 1 | 2016 | 706 | 0.360 |
Why?
| | Lymphangiogenesis | 1 | 2011 | 27 | 0.350 |
Why?
| | Macrophages | 4 | 2024 | 1511 | 0.350 |
Why?
| | Models, Animal | 2 | 2019 | 392 | 0.340 |
Why?
| | Mice, Knockout | 9 | 2025 | 3121 | 0.340 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2014 | 459 | 0.330 |
Why?
| | Protein Folding | 4 | 2009 | 279 | 0.330 |
Why?
| | Macrophages, Alveolar | 6 | 2024 | 368 | 0.330 |
Why?
| | Morphogenesis | 2 | 2016 | 173 | 0.330 |
Why?
| | Liver | 3 | 2019 | 1887 | 0.320 |
Why?
| | 1-Acylglycerophosphocholine O-Acyltransferase | 1 | 2010 | 5 | 0.320 |
Why?
| | Membrane Proteins | 3 | 2014 | 1166 | 0.320 |
Why?
| | Phospholipids | 2 | 2017 | 213 | 0.310 |
Why?
| | Respiration | 1 | 2010 | 206 | 0.300 |
Why?
| | Genetic Vectors | 4 | 2021 | 337 | 0.300 |
Why?
| | Cell Line | 9 | 2017 | 2882 | 0.300 |
Why?
| | Dexamethasone | 3 | 2020 | 372 | 0.290 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 2025 | 106 | 0.290 |
Why?
| | Skin | 2 | 2026 | 755 | 0.280 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2363 | 0.270 |
Why?
| | Mice, Transgenic | 6 | 2017 | 2182 | 0.270 |
Why?
| | Lung Diseases, Interstitial | 2 | 2021 | 660 | 0.250 |
Why?
| | Perfume | 1 | 2026 | 5 | 0.240 |
Why?
| | GTP-Binding Protein alpha Subunit, Gi2 | 1 | 2025 | 5 | 0.230 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2006 | 58 | 0.230 |
Why?
| | Pulmonary Fibrosis | 2 | 2024 | 395 | 0.230 |
Why?
| | Endoplasmic Reticulum | 4 | 2010 | 266 | 0.230 |
Why?
| | Sheep | 4 | 2023 | 880 | 0.230 |
Why?
| | One Health | 1 | 2025 | 10 | 0.230 |
Why?
| | Disinfectants | 1 | 2025 | 46 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2026 | 240 | 0.210 |
Why?
| | Humans | 37 | 2026 | 144759 | 0.210 |
Why?
| | Heat-Shock Proteins | 2 | 2008 | 138 | 0.210 |
Why?
| | Maternal Exposure | 1 | 2025 | 213 | 0.200 |
Why?
| | Prenatal Care | 3 | 2022 | 307 | 0.200 |
Why?
| | Eosinophils | 1 | 2025 | 316 | 0.190 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2019 | 159 | 0.190 |
Why?
| | Epigenomics | 1 | 2023 | 114 | 0.190 |
Why?
| | Mutation | 7 | 2021 | 4089 | 0.180 |
Why?
| | Employment | 1 | 2024 | 188 | 0.180 |
Why?
| | Phosphatidylcholines | 2 | 2013 | 131 | 0.180 |
Why?
| | Gene Expression Profiling | 5 | 2019 | 1782 | 0.180 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 570 | 0.170 |
Why?
| | Cytokine Receptor Common beta Subunit | 2 | 2018 | 2 | 0.170 |
Why?
| | Skin Irritancy Tests | 1 | 2020 | 3 | 0.170 |
Why?
| | Mice, Inbred C57BL | 6 | 2025 | 5992 | 0.170 |
Why?
| | Disease Models, Animal | 8 | 2026 | 4557 | 0.160 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2021 | 154 | 0.160 |
Why?
| | Capsid | 1 | 2020 | 94 | 0.160 |
Why?
| | Odorants | 1 | 2020 | 116 | 0.150 |
Why?
| | Macaca mulatta | 4 | 2021 | 191 | 0.150 |
Why?
| | Exons | 3 | 2013 | 358 | 0.150 |
Why?
| | Premature Birth | 2 | 2020 | 380 | 0.150 |
Why?
| | Medicaid | 1 | 2024 | 461 | 0.150 |
Why?
| | Animals, Newborn | 4 | 2025 | 902 | 0.150 |
Why?
| | Cell Proliferation | 4 | 2020 | 2496 | 0.150 |
Why?
| | Heparin | 1 | 2020 | 244 | 0.150 |
Why?
| | Cholesterol | 2 | 2018 | 406 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2025 | 675 | 0.140 |
Why?
| | Receptors, Glucocorticoid | 1 | 2020 | 138 | 0.140 |
Why?
| | Gene Expression | 3 | 2017 | 1490 | 0.140 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2018 | 30 | 0.140 |
Why?
| | Amyloid | 1 | 2019 | 92 | 0.140 |
Why?
| | Acyl-CoA Oxidase | 1 | 2018 | 2 | 0.140 |
Why?
| | Amino Acids | 1 | 2022 | 521 | 0.140 |
Why?
| | Fetal Development | 1 | 2021 | 299 | 0.140 |
Why?
| | Delivery, Obstetric | 1 | 2019 | 160 | 0.140 |
Why?
| | tau Proteins | 1 | 2019 | 115 | 0.140 |
Why?
| | Memory Disorders | 1 | 2019 | 193 | 0.140 |
Why?
| | Lymphocytes | 1 | 2020 | 382 | 0.130 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 72 | 0.130 |
Why?
| | Erythroblasts | 1 | 2017 | 19 | 0.130 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 21 | 0.130 |
Why?
| | Polycythemia | 1 | 2017 | 25 | 0.130 |
Why?
| | Lipids | 4 | 2024 | 710 | 0.130 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2020 | 319 | 0.130 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 29 | 0.130 |
Why?
| | Transgenes | 2 | 2011 | 189 | 0.130 |
Why?
| | Pseudomonas Infections | 1 | 2019 | 221 | 0.130 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2017 | 118 | 0.130 |
Why?
| | Immunohistochemistry | 3 | 2012 | 1716 | 0.130 |
Why?
| | Biomarkers | 5 | 2023 | 4271 | 0.120 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2018 | 141 | 0.120 |
Why?
| | Myelodysplastic Syndromes | 1 | 2018 | 147 | 0.120 |
Why?
| | Pseudomonas aeruginosa | 1 | 2019 | 356 | 0.120 |
Why?
| | Pregnancy | 7 | 2025 | 7190 | 0.120 |
Why?
| | Neovascularization, Physiologic | 2 | 2009 | 194 | 0.120 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 1 | 2015 | 8 | 0.120 |
Why?
| | Genetic Diseases, Inborn | 1 | 2015 | 44 | 0.110 |
Why?
| | Influenza, Human | 1 | 2021 | 616 | 0.110 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2016 | 148 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1907 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2026 | 2027 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2017 | 636 | 0.110 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 266 | 0.110 |
Why?
| | Fetus | 1 | 2019 | 803 | 0.110 |
Why?
| | Gene Deletion | 3 | 2019 | 389 | 0.110 |
Why?
| | Transfection | 3 | 2009 | 940 | 0.110 |
Why?
| | Salivary Glands | 1 | 2014 | 36 | 0.110 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 439 | 0.100 |
Why?
| | Transcription, Genetic | 2 | 2016 | 1496 | 0.100 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2018 | 370 | 0.100 |
Why?
| | Molecular Chaperones | 2 | 2008 | 200 | 0.100 |
Why?
| | Respiratory Insufficiency | 1 | 2017 | 326 | 0.100 |
Why?
| | Receptors, Purinergic P2Y2 | 1 | 2013 | 4 | 0.100 |
Why?
| | Immunity, Innate | 1 | 2020 | 846 | 0.100 |
Why?
| | Consumer Product Safety | 2 | 2026 | 32 | 0.100 |
Why?
| | Calcinosis | 1 | 2015 | 234 | 0.100 |
Why?
| | Cytomegalovirus | 1 | 2014 | 168 | 0.100 |
Why?
| | Hermanski-Pudlak Syndrome | 1 | 2012 | 2 | 0.100 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2026 | 54 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2019 | 965 | 0.090 |
Why?
| | Analysis of Variance | 2 | 2012 | 1306 | 0.090 |
Why?
| | Immune Sera | 1 | 2011 | 77 | 0.090 |
Why?
| | Computational Biology | 1 | 2017 | 680 | 0.090 |
Why?
| | Glycogen | 1 | 2011 | 54 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2011 | 16 | 0.090 |
Why?
| | Internet | 1 | 2017 | 699 | 0.090 |
Why?
| | Myofibroblasts | 2 | 2026 | 143 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2011 | 557 | 0.090 |
Why?
| | Doxycycline | 1 | 2011 | 62 | 0.090 |
Why?
| | Luciferases | 3 | 2009 | 152 | 0.090 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2011 | 157 | 0.090 |
Why?
| | Liver Neoplasms | 1 | 2018 | 780 | 0.090 |
Why?
| | Immunoblotting | 1 | 2011 | 300 | 0.080 |
Why?
| | Protein Transport | 3 | 2012 | 441 | 0.080 |
Why?
| | Hypoxia | 1 | 2018 | 1199 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 341 | 0.080 |
Why?
| | DNA Primers | 1 | 2011 | 512 | 0.080 |
Why?
| | DNA, Mitochondrial | 1 | 2011 | 211 | 0.080 |
Why?
| | Air | 1 | 2010 | 45 | 0.080 |
Why?
| | Regulatory Factor X Transcription Factors | 2 | 2008 | 11 | 0.080 |
Why?
| | Receptors, Adenosine A2 | 1 | 2009 | 5 | 0.080 |
Why?
| | Female | 13 | 2025 | 78271 | 0.080 |
Why?
| | Protein Structure, Secondary | 1 | 2010 | 369 | 0.070 |
Why?
| | Injections, Intramuscular | 2 | 2019 | 141 | 0.070 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2008 | 26 | 0.070 |
Why?
| | Epitopes | 1 | 2010 | 485 | 0.070 |
Why?
| | Models, Biological | 2 | 2017 | 1821 | 0.070 |
Why?
| | Apoptosis | 2 | 2026 | 2430 | 0.060 |
Why?
| | Phenotype | 3 | 2017 | 3162 | 0.060 |
Why?
| | Homeostasis | 2 | 2023 | 640 | 0.060 |
Why?
| | Administration, Oral | 2 | 2019 | 847 | 0.060 |
Why?
| | Risk Assessment | 3 | 2026 | 3671 | 0.060 |
Why?
| | Microscopy, Fluorescence | 2 | 2009 | 416 | 0.060 |
Why?
| | Transcription Factors | 3 | 2017 | 1741 | 0.060 |
Why?
| | No-Observed-Adverse-Effect Level | 1 | 2026 | 6 | 0.060 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2006 | 12 | 0.060 |
Why?
| | Leupeptins | 1 | 2006 | 12 | 0.060 |
Why?
| | Protein Sorting Signals | 1 | 2006 | 20 | 0.060 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2006 | 49 | 0.060 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2006 | 22 | 0.060 |
Why?
| | Proteasome Inhibitors | 1 | 2006 | 40 | 0.060 |
Why?
| | I-kappa B Proteins | 1 | 2006 | 74 | 0.060 |
Why?
| | Blotting, Western | 2 | 2009 | 1187 | 0.060 |
Why?
| | Zoonoses | 1 | 2025 | 36 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 1137 | 0.060 |
Why?
| | Protein Processing, Post-Translational | 1 | 2008 | 477 | 0.060 |
Why?
| | Caspase 3 | 1 | 2006 | 238 | 0.050 |
Why?
| | Protein Binding | 3 | 2009 | 2273 | 0.050 |
Why?
| | Caspases | 1 | 2006 | 232 | 0.050 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1313 | 0.050 |
Why?
| | Promoter Regions, Genetic | 3 | 2019 | 1257 | 0.050 |
Why?
| | Blood Vessels | 1 | 2006 | 171 | 0.050 |
Why?
| | Dysbiosis | 1 | 2025 | 187 | 0.050 |
Why?
| | Oligopeptides | 1 | 2006 | 269 | 0.050 |
Why?
| | Thyroid Nuclear Factor 1 | 1 | 2023 | 16 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2020 | 6429 | 0.050 |
Why?
| | Ligands | 1 | 2026 | 673 | 0.050 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2026 | 279 | 0.050 |
Why?
| | Actins | 1 | 2026 | 425 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2024 | 68 | 0.050 |
Why?
| | Cellular Senescence | 1 | 2026 | 226 | 0.050 |
Why?
| | Hippocampus | 2 | 2019 | 965 | 0.050 |
Why?
| | Down-Regulation | 1 | 2006 | 627 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2003 | 276 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2009 | 869 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1180 | 0.050 |
Why?
| | Pneumonia | 2 | 2020 | 631 | 0.050 |
Why?
| | Up-Regulation | 1 | 2006 | 851 | 0.050 |
Why?
| | Cell Survival | 1 | 2006 | 1098 | 0.050 |
Why?
| | History, 20th Century | 1 | 2024 | 325 | 0.050 |
Why?
| | DNA-Binding Proteins | 2 | 2008 | 1499 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2018 | 1455 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2003 | 381 | 0.040 |
Why?
| | Transcriptome | 2 | 2019 | 1045 | 0.040 |
Why?
| | Male | 7 | 2026 | 72315 | 0.040 |
Why?
| | Gene Knock-In Techniques | 1 | 2021 | 61 | 0.040 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2021 | 56 | 0.040 |
Why?
| | Steroids | 1 | 2022 | 160 | 0.040 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2637 | 0.040 |
Why?
| | Fibrosis | 1 | 2023 | 548 | 0.040 |
Why?
| | Models, Genetic | 1 | 2003 | 536 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2006 | 748 | 0.040 |
Why?
| | Sepharose | 1 | 2020 | 32 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2730 | 0.040 |
Why?
| | Time Factors | 2 | 2019 | 7173 | 0.040 |
Why?
| | Health Policy | 1 | 2024 | 400 | 0.040 |
Why?
| | Chorioamnionitis | 1 | 2020 | 45 | 0.040 |
Why?
| | Promyelocytic Leukemia Zinc Finger Protein | 1 | 2020 | 8 | 0.040 |
Why?
| | Receptor, IGF Type 1 | 1 | 2020 | 64 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 983 | 0.040 |
Why?
| | Capsid Proteins | 1 | 2020 | 95 | 0.040 |
Why?
| | Cytokines | 2 | 2018 | 2061 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2023 | 2832 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2003 | 737 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 626 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 142 | 0.040 |
Why?
| | Diet | 2 | 2018 | 1273 | 0.040 |
Why?
| | Bronchoalveolar Lavage | 1 | 2018 | 89 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2019 | 423 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2017 | 12 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2020 | 348 | 0.030 |
Why?
| | Gene Order | 1 | 2017 | 27 | 0.030 |
Why?
| | Inflammation | 2 | 2020 | 2878 | 0.030 |
Why?
| | Surface-Active Agents | 1 | 2018 | 92 | 0.030 |
Why?
| | Cell Death | 1 | 2019 | 383 | 0.030 |
Why?
| | Adipose Tissue, Brown | 1 | 2018 | 59 | 0.030 |
Why?
| | RNA Interference | 2 | 2009 | 476 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1886 | 0.030 |
Why?
| | Point Mutation | 1 | 2018 | 243 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 320 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2017 | 275 | 0.030 |
Why?
| | Hepatocytes | 1 | 2018 | 223 | 0.030 |
Why?
| | DNA | 1 | 2003 | 1463 | 0.030 |
Why?
| | Erythropoietin | 1 | 2017 | 100 | 0.030 |
Why?
| | Neuronal Plasticity | 1 | 2019 | 309 | 0.030 |
Why?
| | PPAR gamma | 1 | 2017 | 176 | 0.030 |
Why?
| | Placenta | 1 | 2023 | 780 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2017 | 169 | 0.030 |
Why?
| | Gestational Age | 1 | 2019 | 975 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2018 | 288 | 0.030 |
Why?
| | Fear | 1 | 2019 | 366 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 2017 | 510 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 611 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2017 | 415 | 0.030 |
Why?
| | Learning | 1 | 2019 | 452 | 0.030 |
Why?
| | Fatty Acids | 1 | 2018 | 450 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 384 | 0.030 |
Why?
| | Phosphates | 1 | 2015 | 180 | 0.030 |
Why?
| | Epithelium | 1 | 2015 | 314 | 0.030 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2020 | 410 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 509 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2018 | 453 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2017 | 467 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2017 | 784 | 0.030 |
Why?
| | Asthma | 1 | 2025 | 1767 | 0.030 |
Why?
| | Adaptor Protein Complex 3 | 1 | 2012 | 3 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1694 | 0.020 |
Why?
| | Developmental Disabilities | 1 | 2014 | 281 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2014 | 1253 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2012 | 193 | 0.020 |
Why?
| | Software | 1 | 2017 | 690 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.020 |
Why?
| | Mitochondria | 1 | 2018 | 984 | 0.020 |
Why?
| | Bleomycin | 1 | 2012 | 253 | 0.020 |
Why?
| | Synapses | 1 | 2014 | 439 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2023 | 17066 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 508 | 0.020 |
Why?
| | Pneumonectomy | 1 | 2012 | 169 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2847 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2012 | 769 | 0.020 |
Why?
| | Microscopy, Immunoelectron | 1 | 2009 | 43 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1982 | 0.020 |
Why?
| | Amino Acids, Dicarboxylic | 1 | 2009 | 9 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2009 | 49 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 139 | 0.020 |
Why?
| | Response Elements | 1 | 2009 | 89 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1382 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2009 | 321 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1325 | 0.020 |
Why?
| | Valosin Containing Protein | 1 | 2008 | 8 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1539 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2009 | 247 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 2608 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2008 | 106 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2008 | 151 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1462 | 0.020 |
Why?
| | Cytosol | 1 | 2008 | 227 | 0.020 |
Why?
| | Adenosine Triphosphatases | 1 | 2008 | 162 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1985 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2115 | 0.020 |
Why?
| | Binding Sites | 1 | 2009 | 1329 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 758 | 0.010 |
Why?
| | United States | 1 | 2024 | 15966 | 0.010 |
Why?
| | Aged | 2 | 2018 | 25913 | 0.010 |
Why?
| | Cell Movement | 1 | 2009 | 965 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 3077 | 0.010 |
Why?
| | Cell Cycle Proteins | 1 | 2008 | 628 | 0.010 |
Why?
| | Middle Aged | 2 | 2018 | 35875 | 0.010 |
Why?
| | Registries | 1 | 2012 | 2385 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 5408 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 4154 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5960 | 0.010 |
Why?
| | Rats | 1 | 2009 | 5597 | 0.010 |
Why?
| | Neoplasms | 1 | 2014 | 2875 | 0.010 |
Why?
| | Insulin | 1 | 2008 | 2507 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2012 | 11679 | 0.010 |
Why?
| | Adult | 1 | 2017 | 40449 | 0.010 |
Why?
|
|
Bridges's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|